Abstract:Hutchinson-Gilford progeria syndrome (HGPS or progeria) is typically caused by a dominant-negative C•G-to-T•A mutation (c.1824 C>T; p.G608G) in LMNA, the gene that encodes nuclear lamin A. This mutation causes RNA mis-splicing that produces progerin, a toxic protein that induces rapid ageing and shortens the lifespan of children with progeria to approximately 14 years1-4. Adenine base editors (ABEs) convert targeted A•T base pairs to G•C base pairs with minimal by-products and without requiring double-strand DNA breaks or donor DNA templates5,6. Here we describe the use of an ABE to directly correct the pathogenic HGPS mutation in cultured fibroblasts derived from children with progeria and in a mouse model of HGPS. Lentiviral delivery of the ABE to fibroblasts from children with HGPS resulted in 87-91% correction of the pathogenic allele, mitigation of RNA mis-splicing, reduced levels of progerin and correction of nuclear abnormalities. Unbiased off-target DNA and RNA editing analysis did not detect off-target editing in treated patient-derived fibroblasts. In transgenic mice that are homozygous for the human LMNA c.1824 C>T allele, a single retro-orbital injection of adeno-associated virus 9 (AAV9) encoding the ABE resulted in substantial, durable correction of the pathogenic mutation (around 20-60% across various organs six months after injection), restoration of normal RNA splicing and reduction of progerin protein levels. In vivo base editing rescued the vascular pathology of the mice, preserving vascular smooth muscle cell counts and preventing adventitial fibrosis. A single injection of ABE-expressing AAV9 at postnatal day 14 improved vitality and greatly extended the median lifespan of the mice from 215 to 510 days. These findings demonstrate the potential of in vivo base editing as a possible treatment for HGPS and other genetic diseases by directly correcting their root cause.

Whole-brain in vivo base editing reverses behavioral changes in Mef2c-mutant mice

Whole-brain in vivo base editing reverses autistic-like behaviors in mice

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

Induction of core symptoms of autism spectrum disorder by in vivo CRISPR/Cas9-based gene editing in the brain of adolescent rhesus monkeys

Amelioration of Metabolic and Behavioral Defects Through Base Editing in the PahR408W Phenylketonuria Mouse Model

NitroSynapsin Therapy for a Mouse MEF2C Haploinsufficiency Model of Human Autism

Targeted RNA editing in brainstem alleviates respiratory dysfunction in a mouse model of Rett syndrome

Effective Gene Editing by High-Fidelity Base Editor 2 in Mouse Zygotes

In Vivo Base Editing Rescues Hutchinson–Gilford Progeria Syndrome in Mice

Cell-Type-Specific Gene Inactivation and in Situ Restoration Via Recombinase-Based Flipping of Targeted Genomic Region

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG

DdCBE Mediates Efficient and Inheritable Modifications in Mouse Mitochondrial Genome.

Adenine Base Editing in an Adult Mouse Model of Tyrosinaemia

Visualization and Correction of Social Abnormalities-Associated Neural Ensembles in Adult MECP2 Duplication Mice.

In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model

In Vivo Adenine Base Editing Corrects Newborn Murine Model of Hurler Syndrome

Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy

Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts

Amelioration of an Inherited Metabolic Liver Disease through Creation of a De Novo Start Codon by Cytidine Base Editing.

Eliminating Base-Editor-induced Genome-Wide and Transcriptome-Wide Off-Target Mutations